Sionna Therapeutics closed at $3.73 on Nov 4, up 2.19%, 92.7% below its 52-week closing high. Volume of 687.4K shares was 0.71× its 20-day average (below normal).
Split-adjusted performance: -21.5% over one month, -91.4% over six months, -89.7% over one year.
Short interest was 3.7M shares at the Oct 15 settlement, down 3.2% from the prior report (19.3% of float, 3.7 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| SIONSionna Therapeutics | $3.73 | +2.19% | −91.4% | — | — | — | $168.6M | |
| PEPGPepGen | $2.45 | −0.41% | +32.8% | — | — | — | $169.7M | Compare |
| INOInovio Pharmaceuticals | $1.62 | −2.41% | +30.6% | — | — | — | $167.5M | Compare |
| ZNTLZentalis Pharmaceuticals | $1.76 | −1.12% | −57.9% | — | — | — | $166.6M | Compare |
| ORMPOramed Pharmaceuticals | $4.13 | +3.25% | +5.4% | — | — | 1.0 | $171.8M | Compare |
| ANTXAN2 Therapeutics | $4.25 | +1.67% | −8.6% | — | — | — | $160.4M | Compare |
| WHWKWhitehawk Therapeutics | $3.17 | +2.26% | −23.6% | — | — | — | $180.7M | Compare |
| BBOTBridgeBio Oncology Therapeutics | $2.30 | −0.86% | −72.4% | — | — | — | $184.4M | Compare |
| ALXOALX Oncology Holdings | $1.36 | +5.43% | −34.9% | — | — | — | $188.1M | Compare |
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
